NCT07115550View on ClinicalTrials.gov

A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

August 26, 2027

Study Completion Date

August 26, 2028

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG

Iparomlimab and Tuvonralimab Injection (QL1706) in combination with Regorafenib

All Listed Sponsors

lead

Huai'an First People's Hospital

OTHER

NCT07115550 - A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter